AIMS: Mitochondrial DNA (mtDNA) content is essential for maintaining normal mitochondrial function, and the mitochondrial function is critical for the production and the release of insulin in Type 2 diabetes mellitus. We investigated whether peripheral blood mtDNA content was reduced in Type 2 diabetes, and what were the major factors? METHODS: The mtDNA content of peripheral blood in a sample of 147 Type 2 diabetes and 170 normal Chinese subjects was determined by amplification of the mitochondrial gene CYT-B and normalized by a nuclear DNA β-globin gene. Fasting plasma glucose, HbA(1c) , fasting plasma insulin and lipid profile (HDL-cholesterol, LDL-cholesterol, total cholesterol, triglyceride) were analysed with commercial kits on an automatic analyser. RESULTS: In Type 2 diabetes group, the mean HbA(1c) was 62 mmol/mol (7.8%). Moreover, BMI, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, LDL-cholesterol, triglyceride, fasting plasma insulin and homeostasis model assessment for insulin resistance were significantly higher in Type 2 diabetes group than that in control group. Peripheral blood mtDNA content was 24% lower than that in the controls (1.4 ± 0.5 vs. 1.8 ± 0.7, P < 0.001). The mtDNA content was negatively correlated with BMI, fasting plasma glucose, fasting plasma insulin, homeostasis model assessment for insulin resistance (P < 0.01), and age, triglyceride and LDL-cholesterol levels (P < 0.05); while positively correlated with HDL-cholesterol level (P < 0.05) in both groups. Stepwise regression analysis indicated that HbA(1c), fasting plasma glucose and age of onset were the major factors affecting the mtDNA content in the Type 2 diabetes group; however, BMI was the only variable associated with lower mtDNA content in control group. CONCLUSION: Our results demonstrate that lower peripheral blood mtDNA content is associated with Type 2 diabetes in Chinese individuals, and HbA(1c), fasting plasma glucose and age of onset are the major factors affecting the mtDNA content.
AIMS: Mitochondrial DNA (mtDNA) content is essential for maintaining normal mitochondrial function, and the mitochondrial function is critical for the production and the release of insulin in Type 2 diabetes mellitus. We investigated whether peripheral blood mtDNA content was reduced in Type 2 diabetes, and what were the major factors? METHODS: The mtDNA content of peripheral blood in a sample of 147 Type 2 diabetes and 170 normal Chinese subjects was determined by amplification of the mitochondrial gene CYT-B and normalized by a nuclear DNA β-globin gene. Fasting plasma glucose, HbA(1c) , fasting plasma insulin and lipid profile (HDL-cholesterol, LDL-cholesterol, total cholesterol, triglyceride) were analysed with commercial kits on an automatic analyser. RESULTS: In Type 2 diabetes group, the mean HbA(1c) was 62 mmol/mol (7.8%). Moreover, BMI, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, LDL-cholesterol, triglyceride, fasting plasma insulin and homeostasis model assessment for insulin resistance were significantly higher in Type 2 diabetes group than that in control group. Peripheral blood mtDNA content was 24% lower than that in the controls (1.4 ± 0.5 vs. 1.8 ± 0.7, P < 0.001). The mtDNA content was negatively correlated with BMI, fasting plasma glucose, fasting plasma insulin, homeostasis model assessment for insulin resistance (P < 0.01), and age, triglyceride and LDL-cholesterol levels (P < 0.05); while positively correlated with HDL-cholesterol level (P < 0.05) in both groups. Stepwise regression analysis indicated that HbA(1c), fasting plasma glucose and age of onset were the major factors affecting the mtDNA content in the Type 2 diabetes group; however, BMI was the only variable associated with lower mtDNA content in control group. CONCLUSION: Our results demonstrate that lower peripheral blood mtDNA content is associated with Type 2 diabetes in Chinese individuals, and HbA(1c), fasting plasma glucose and age of onset are the major factors affecting the mtDNA content.
Authors: Xue Liu; Ryan J Longchamps; Kerri L Wiggins; Laura M Raffield; Lawrence F Bielak; Wei Zhao; Achilleas Pitsillides; Thomas W Blackwell; Jie Yao; Xiuqing Guo; Nuzulul Kurniansyah; Bharat Thyagarajan; Nathan Pankratz; Stephen S Rich; Kent D Taylor; Patricia A Peyser; Susan R Heckbert; Sudha Seshadri; L Adrienne Cupples; Eric Boerwinkle; Megan L Grove; Nicholas B Larson; Jennifer A Smith; Ramachandran S Vasan; Tamar Sofer; Annette L Fitzpatrick; Myriam Fornage; Jun Ding; Adolfo Correa; Goncalo Abecasis; Bruce M Psaty; James G Wilson; Daniel Levy; Jerome I Rotter; Joshua C Bis; Claudia L Satizabal; Dan E Arking; Chunyu Liu Journal: Cell Genom Date: 2021-10-13
Authors: Adrienne Tin; Morgan E Grams; Foram N Ashar; John A Lane; Avi Z Rosenberg; Megan L Grove; Eric Boerwinkle; Elizabeth Selvin; Josef Coresh; Nathan Pankratz; Dan E Arking Journal: J Am Soc Nephrol Date: 2016-01-21 Impact factor: 10.121
Authors: Louise D Zheng; Leah E Linarelli; Longhua Liu; Sarah S Wall; Mark H Greenawald; Richard W Seidel; Paul A Estabrooks; Fabio A Almeida; Zhiyong Cheng Journal: Clin Epigenetics Date: 2015-06-10 Impact factor: 6.551
Authors: Louise D Zheng; Leah E Linarelli; Joseph Brooke; Cayleen Smith; Sarah S Wall; Mark H Greenawald; Richard W Seidel; Paul A Estabrooks; Fabio A Almeida; Zhiyong Cheng Journal: Oxid Med Cell Longev Date: 2016-05-19 Impact factor: 6.543